Genotoxic evaluation of two oral antidiabetic agents in the Drosophila wing spot test

Guerbuezel M., Capoglu I., Kizilet H., HALICI Z., ÖZÇİÇEK F., DEMİRTAŞ L.

TOXICOLOGY AND INDUSTRIAL HEALTH, vol.30, no.4, pp.376-383, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 4
  • Publication Date: 2014
  • Doi Number: 10.1177/0748233712456091
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.376-383
  • Erzincan Binali Yildirim University Affiliated: Yes


In this study, two sulfonylureas-glimepiride and glipizide-commonly used in type 2 diabetes mellitus were investigated for genotoxicity in the Drosophila wing spot test. For this purpose, three-day-old transheterozygous larvae were treated with three mutagenic compounds, and the results obtained were compared with the control group. Mutational or recombinogenic changes were recorded in two recessive genes-multiple wing hairs (mwh) and flare (flr(3)). Two recessive markers were located on the left arm of chromosome 3, mwh in map position 0.3, and flare-3 (flr3) at 38.8, while the centromere was located in position 47.7. Wing spot tests are targeted on the loss of heterozygosity, which may be grounded in different genetic mechanisms such as mutation, mitotic recombination, deletion, half-translocation, chromosome loss, or nondisjunction. Genetic changes formatting in somatic cells of the imaginal discs cause nascence different mutant cloning in different body parts of adult flies. Our in vivo experiments demonstrated that glimepiride and glipizide show the genotoxicity, which is especially dependent on homologous somatic recombination.